Emyria (ASX:EMD) - Managing Director, Michael Winlo
Managing Director, Michael Winlo
Source: Emyria
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) receives positive results from the first batch of MDMA analogues screened for neuroreceptor activity from pharmaceutical development company, Eurofin
  • Results highlighted novel compounds with greater potency compared with MDMA for certain neuroreceptors at the test concentrations
  • The company says the early results are promising, with very few compounds excluded due to possible off-target concerns at the test concentrations
  • A second batch of compounds from the original analogue library is now being prepared for initial screening
  • Emyria is up 6.67 per cent, trading at 40 cents at 1:40 pm AEDT

Emyria (EMD) has received ‘positive’ results from the first MDMA analogues screened for neuroreceptor activity.

In-vitro receptor screening results from the first batch of MDMA analogues were received from the pharmaceutical development company, Eurofin.

Results highlighted novel compounds with greater potency compared with MDMA for certain neuroreceptors at the test concentrations.

Sixty-six of 68 compounds from the initial batch successfully passed screening, showing no evidence of interactions with one or more of the “anti-targets,” or enzyme or cell receptor interactions associated with unwanted side effects, at the test concentrations.

Emyria’s Managing Director, Michael Winlo said the early results are promising, with very few compounds excluded due to possible off-target concerns at the test concentrations.

“These results mean we have multiple compounds with therapeutic potential suitable for further screening and development,” Dr Winlo said.

The second batch of compounds from the original analogue library is now being prepared for initial screening.

Meanwhile, Emyria’s first patent has been filed and further IP filing is in progress.

Emyria was up 6.67 per cent, trading at 40 cents at 1:40 pm AEDT.  
 

EMD by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece